Valeant Pharmaceuticals International Inc (VRX): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Valeant Pharmaceuticals International ( VRX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.2%. By the end of trading, Valeant Pharmaceuticals International fell $1.29 (-1.2%) to $107.90 on average volume. Throughout the day, 1,095,768 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1,112,200 shares. The stock ranged in price between $106.74-$109.55 after having opened the day at $109.21 as compared to the previous trading day's close of $109.19. Other companies within the Drugs industry that declined today were: Ambit Biosciences ( AMBI), down 33.1%, Vanda Pharmaceuticals ( VNDA), down 8.2%, Pernix Therapeutics Holdings ( PTX), down 7.9% and Conatus Pharmaceuticals ( CNAT), down 6.9%.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $36.6 billion and is part of the health care sector. Shares are up 82.7% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk.

On the positive front, Tonix Pharmaceuticals ( TNXP), up 30.1%, ARCA biopharma ( ABIO), up 25.0%, Idera Pharmaceuticals ( IDRA), up 21.9% and Bind Therapeutics ( BIND), up 14.6% , were all gainers within the drugs industry with ACADIA Pharmaceuticals ( ACAD) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Super Bowl of Earnings: Cramer's 'Mad Money' Recap (Friday 1/26/18)

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

Valeant CEO: Drugmaker Knee-Deep in 'Turnaround Effort of a Lifetime'

5 Things We Learned About Activist Investing in 2017

5 Things We Learned About Activist Investing in 2017

Valeant Pharmaceuticals Stock Still a Dog?

Valeant Pharmaceuticals Stock Still a Dog?

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)

No Two Stocks Are the Same: Cramer's 'Mad Money' Recap (Tuesday 12/12/17)